Journal Mobile Options
Table of Contents
Vol. 2, No. 3-4, 2005
Issue release date: January 2006
Neurodegenerative Dis 2005;2:195–201

Lead Exposure as a Risk Factor for Amyotrophic Lateral Sclerosis

Kamel F. · Umbach D.M. · Hu H. · Munsat T.L. · Shefner J.M. · Taylor J.A. · Sandler D.P.
aNational Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, N.C.; bHarvard Medical School and Harvard School of Public Health and cNew England Medical Center, Cambridge, Mass., and dSUNY Upstate Medical University, Syracuse, N.Y., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The etiology of amyotrophic lateral sclerosis (ALS) likely involves an environmental component. We qualitatively assessed literature on ALS and lead exposure. Problems of study design make case reports and studies of lead in blood or tissues difficult to interpret. Most previous case-control studies found an association of ALS with self-reported occupational exposure to lead, with increased risks of 2- to >4-fold. However, these results may have been affected by recall bias. Objective: To address inconsistencies among published reports, we used both lead biomarkers and interview data to assess lead exposure, and we evaluated the role of genetic susceptibility to lead. Methods: We conducted a case-control study in New England in 1993–1996 with 109 ALS cases and 256 population-based controls. We measured blood and bone lead levels, the latter using X-ray fluorescence, and interviewed participants regarding sources of lead exposure. Results: In our study, ALS was associated with self-reported occupational lead exposure, with a dose response for cumulative days of exposure. ALS was also associated with blood and bone lead levels, with a 1.9-fold increase in risk for each µg/dl increment in blood lead and a 2.3- to 3.6-fold increase for each doubling of bone lead. A polymorphism in the δ-aminolevulinic acid dehydratase gene was associated with a 1.9-fold increase in ALS risk. Conclusion: These results, together with previous studies, suggest that lead exposure plays a role in the etiology of ALS. An increase in mobilization of lead from bone into blood may play a role in the acute onset of disease.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kunst CB: Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 2004;75:933–947.
  2. Nelson LM: Epidemiology of ALS. Clin Neurosci 1995/1996;3:327–331.
  3. Strong M, Rosenfeld J: Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:136–143.
  4. Cox P, Banack S, Murch S: Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA 2003;100:13380–13383.
  5. Mitchell JD: Amyotrophic lateral sclerosis: toxins and environment. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:235–250.
  6. Kurland LT, Radhakrishnan K, Smith GE, Armon C, Nemetz PN: Mechanical trauma as a risk factor in classic amyotrophic lateral sclerosis – lack of epidemiologic evidence. J Neurol Sci 1992;113:133–143.
  7. Cruz DC, Nelson LM, McGuire V, Longstreth WT Jr: Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology 1999;18:101–110.
  8. Chio A, Benzi G, Dossena M, Mutani R, Mora G: Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005;128:472–476.
  9. Horner R, Kamins K, Feussner J, Grambow SC, Hoff-Lindquist J, Harati Y, Mitsumoto H, Pascuzzi R, Spencer PS, Tim R, Howard D, Smith TC, Ryan MAK, Coffman CJ, Kasarskis EJ: Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003;61:742–749.
  10. Deapen D, Henderson B: A case-control study of amyotrophic lateral sclerosis. Am J Epidemiol 1986;123:790–799.
  11. Savettieri G, Salemi G, Arcara A, Cassata M, Castiglione MG, Fierro B:A case-control study of amyotrophic lateral sclerosis. Neuroepidemiology 1991;10:242–245.
  12. McGuire V, Longstreth W Jr, Nelson L, Koepsell TD, Checkoway H, Morgan MS, van Belle G: Occupational exposures and amyotrophic lateral sclerosis: a population-based case-control study. Am J Epidemiol 1997;145:1076–1088.
  13. Burns CJ, Beard KK, Cartmill JB: Mortality in chemical workers potentially exposed to 2,4-dichlorophenoxyacetic acid, 1945–94: an update. Occup Environ Med 2001;58:24–30.
  14. Gunnarsson LG, Bodin L, Soderfeldt B, Axelson O: A case-control study of motor neurone disease – its relation to heritability, and occupational exposures, particularly to solvents. Br J Ind Med 1992;49:791–798.
  15. Davanipour Z, Sobel E, Bowman JD, Qian Z, Will AD: Amyotrophic lateral sclerosis and occupational exposure to electromagnetic fields. Bioelectromagnetics 1997;18:28–35.
  16. Savitz DA, Checkoway H, Loomis DP: Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology 1998;9:398–404.
  17. Johansen C, Olsen JH: Mortality from amyotrophic lateral sclerosis, other chronic disorders, and electric shocks among utility workers. Am J Epidemiol 1998;148:362–368.
  18. Noonan CW, Reif JS, Yost M, Touchstone J: Occupational exposure to magnetic fields in case-referent studies of neurodegenerative diseases. Scand J Work Environ Health 2002;28:42–48.
  19. Hakansson N, Gustavsson P, Johansen C, Floderus B: Neurodegenerative diseases in welders and other workers exposed to high levels of magnetic fields. Epidemiology 2003;14:420–426.
  20. Livesley B, Sissons CE: Chronic lead intoxication mimicking motor neurone disease. Br Med J 1968;iv:387–388.
  21. Boothby JA, Rowland LP: Reversible forms of motor neuron disease – lead ‘neuritis’. Arch Neurol 1974;31:18–23.
  22. Petkau A, Sawatzky A, Hillier CR, Hoogstraten J: Lead content of neuromuscular tissue in amyotrophic lateral sclerosis: case report and other considerations. Br J Ind Med 1974;31:275–287.
  23. Simpson JA, Seaton DA, Adams JF: Response to treatment with chelating agents of anaemia, chronic encephalopathy, and myelopathy due to lead poisoning. J Neurol Neurosurg Psychiatry 1984;27:536–541.
  24. Couratier P, Bernet Bernady P, Truong T, Lagrange E, Preux PM, Lachatre G, Vallat JM: Lead intoxication and amyotrophic lateral sclerosis. Rev Neurol Paris 1998;154:345–347.
  25. Currier RD, Haerer AF: Amyotrophic lateral sclerosis and metallic toxins. Arch Environ Health 1968;17:712–719.
  26. Campbell AMG, Williams ER, Barltrop D: Motor neuron disease and exposure to lead. J Neurol Neurosurg Psychiatry 1970;33:220–226.
  27. Conradi S, Ronnevi LO, Vesterberg O: Increased plasma levels of lead in patients with amyotrophic lateral sclerosis compared with control subjects as determined by flameless atomic absorption spectrophotometry. J Neurol Neurosurg Psychiatry 1978;41:389–393.
  28. Conradi S, Ronnevi LO, Vesterberg O: Lead concentration in skeletal muscle in amyotrophic lateral sclerosis patients and control subjects. J Neurol Neurosurg Psychiatry 1978;41:1001–1004.
  29. House AO, Abbot RJ, Davidson DLW: Response to penicillamine of lead concentrations in CSF and blood of patients with motor neurone disease. Br Med J 1978;ii:1684.
  30. Kurlander HM, Patten BM: Metals in spinal cord tissue of patients dying of motor neuron disease. Ann Neurol 1979;6:21–24.
  31. Conradi S, Ronnevi LO, Nise G, Vesterberg O: Abnormal distribution of lead in amyotrophic lateral sclerosis – re-estimation of lead in the cerebrospinal fluid. J Neurol Sci 1980;48:413–418.
  32. Pierce-Ruhland R, Patten BM: Muscle metals in motor neurone disease. Ann Neurol 1980;8:193–195.
  33. Stober T, Stelte W, Kunze K: Lead concentrations in blood, plasma, erythrocytes, and cerebrospinal fluid in amyotrophic lateral sclerosis. J Neurol Sci 1983;61:21–26.
  34. Cavalleri A, Minoia C, Ceroni M, Poloni M: Lead in cerebrospinal fluid and its relationship to plasma lead in humans. J Appl Toxicol 1984;4:63–65.
  35. Vinceti M, Guidetti D, Bergomi M, Caselgrandi E, Vivoli R, Olmi M, Rinaldi L, Rovesti S, Solime F: Lead, cadmium, and selenium in the blood of patients with sporadic amyotrophic lateral sclerosis. Ital J Neurol Sci 1997;18:87–92.
  36. Felmus MT, Patten BM, Swanke L: Antecedent events in amyotrophic lateral sclerosis. Neurology 1976;26:167–172.
  37. Pierce-Ruhland R, Patten BM: Repeat study of antecedent events in motor neuron disease. Ann Clin Res 1981;13:102–107.
  38. Gresham LS, Molgaard CA, Golbeck AL, Smith R: Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology 1986;5:29–38.
  39. Armon C, Kurland LT, Daube JR, O’Brien PC: Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991;41:1077–1084.
  40. Chancellor AM, Slattery JM, Fraser H, Warlow CP: Risk factors for motor neuron disease – a case-control study based on patients from the Scottish motor neuron disease register. J Neurol Neurosurg Psychiatry 1993;56:1200–1206.
  41. Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP:Lead exposure and amyotrophic lateral sclerosis. Epidemiology 2002;13:311–319.
  42. Aro ACA, Todd AC, Amarasiriwardena C, Hu H: Improvements in the calibration of 109CD K x-ray fluorescence systems for measuring bone lead in vivo. Phys Med Biol 1994;39:2263–2271.
  43. Kamel F, Umbach DM, Lehman T, Park LP, Munsat TL, Shefner JM, Sandler DP, Hu H, Taylor JA: Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the δ-aminolevulinic acid dehydratase and vitamin D receptor genes. Environ Health Perspect 2003;111:1335–1339.
  44. Hu H, Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, Rotnitsky A: Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. Am J Epidemiol 1996;144:749–759.
  45. Kelada SN, Shelton E, Kaufmann RB, Khoury MJ: δ-Aminolevulinic acid dehydratase genotype and lead toxicity: a HuGE review. Am J Epidemiol 2001;154:1–13.
  46. Smith CM, Wang X, Hu H, Kelsey KT: A polymorphism in the δ-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect 1995;103:248–253.
  47. Alexander BH, Checkoway H, Costa-Mallen P, Faustman EM, Woods JS, Kelsey KT, van Netten C, Costa LG: Interaction of blood lead and δ-aminolevulinic acid dehydratase genotype on markers of heme synthesis and sperm production in lead smelter workers. Environ Health Perspect 1998;106:213–216.
  48. Lee BK, Lee GS, Stewart WF, Ahn KD, Simon D, Kelsey KT, Todd AC, Schwartz BS: Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and δ-aminolevulinic acid dehydratase genes. Environ Health Perspect. 2001;109:383–389.
  49. Lee SS, Lee BK, Lee GS, Stewart WF, Simon D, Kelsey K, Todd AC, Schwartz BS: Associations of lead biomarkers and δ-aminolevulinic acid dehydratase and vitamin D receptor genotypes with hematopoietic outcomes in Korean lead workers. Scand J Work Environ Health 2001;27:402–411.
  50. Wu MT, Kelsey K, Schwartz J, Sparrow D, Weiss S, Hu H: δ-Aminolevulinic acid dehydratase polymorphism may modify the relationship of low-level lead exposure to uricemia and renal function: the Normative Aging Study. Environ Health Perspect 2003;111:335–341.
  51. Kim HS, Lee SS, Lee GS, Hwangbo Y, Ahn KD, Lee BK: The protective effect of δ-aminolevulinic acid dehydratase 1-2 and 2-2 isozymes against blood lead with higher hematologic parameters. Environ Health Perspect 2004;112:538–541.
  52. Fleming DEB, Chettle DR, Wetmur JG, Desnick RJ, Robin JP, Bouleay D, Richard NS, Gordon CL, Webber CE: Effect of the δ-aminolevulinate dehydratase polymorphism on the accumulation of lead in bone and blood in lead smelter workers. Environ Res 1998;77:49–61.
  53. Hu H, Wu MT, Cheng Y, Sparrow D, Weiss S, Kelsey K: The δ-aminolevulinic acid dehydratase polymorphism and bone and blood lead levels in community-exposed men: the Normative Aging Study. Environ Health Perspect 2001;109:827–832.
  54. Lidsky TI, Schneider JS: Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003;126:5–19.
  55. Suszkiw JB: Presynaptic disruption of transmitter release by lead. Neurotoxicology 2004;25:599–604.
  56. Arasaki K, Kato Y, Hyodo A, Ushijima R, Tamaki M: Longitudinal study of functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve 2002;25:520–526.
  57. Shefner J, Cudkowicz M, Brown R: Comparison of incremental with multipoint MUNE methods in transgenic ALS mice. Muscle Nerve 2002;25:39–42.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50